ArticleInternational journal of retina and vitreous2025
The clinical features and real world treatment outcomes in von Hippel Lindau related retinal capillary hemangioblastomas.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Concurrent Von Hippel-Lindau disease and enhanced S-cone syndrome leading to a distinct retinal phenotype.American journal of ophthalmology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveTo present the clinical features and outcomes of treatment in von Hippel-Lindau (VHL) related retinal capillary hemangioblastoma (RCH).
methodsA retrospective interventional cohort study that included Patients who were diagnosed with VHL-related RCH from 2014 to 2024 at a tertiary referral center.
resultsThirty-two eyes of 18 patients with VHL-associated RCH were included. Treatment was indicated in 30 eyes (90.9%), and the indications for treatment were tumor leakage and subretinal fluids (SRF) with or without exudative retinal detachments in 25 eyes (83.3%) and tractional/exudative retinal detachments (T-ERD) in 4 eyes (13.3%). Significantly worse visual outcomes were observed in patients who had lower BCVA on presentation, larger tumor sizes, developed retinal complications, underwent retinal surgery, detached retina on the last follow up and had persistent tumor outcomes.
conclusionThe management outcomes in VHL-related RCH depend on the lesionsize and location, severity of the clinical picture on presentation and the development of complications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.